Company news

LB Pharmaceuticals Inc news in 2026

LB Pharmaceuticals Inc's news releases, calls and decks from 2026, newest first.

View company

LB Pharmaceuticals to Participate in Upcoming Investor Events

October 15, 2026

LB Pharmaceuticals Presents New Preclinical Data Supporting LB-102’s Bimodal Mechanism of Action and Highlights Ongoing Late-Stage Clinical Development Programs at the 39th ECNP Congress

October 10, 2026

LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4)

October 9, 2026

LB Pharmaceuticals to Host In-Person and Virtual R&D Day on October 27, 2026: Advancing LB‑102 with a Focus on Schizophrenia Treatment

October 6, 2026

LB Pharmaceuticals Appoints Susan G. Kozauer, M.D. as Chief Medical Officer

September 15, 2026

LB Pharmaceuticals to Participate in Upcoming September Investor Events

September 3, 2026

LB Pharmaceuticals Appoints Joseph Miller as Chief Financial Officer

September 3, 2026

LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 11, 2026

LB Pharmaceuticals Announces $150 Million Private Placement

July 29, 2026

LB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophrenia

July 22, 2026

LB Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical Operations

June 30, 2026

LB Pharmaceuticals to Participate in Upcoming June Investor Events

May 28, 2026

LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 12, 2026

LB Pharmaceuticals Announces Publication in JAMA Psychiatry of Results from Phase 2 NOVA-1 Trial of LB-102 in Schizophrenia

April 22, 2026

LB Pharmaceuticals Announces Presentation at 25th Annual Needham Virtual Healthcare Conference

April 8, 2026

LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102’s Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)

March 26, 2026

LB Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

March 25, 2026

LB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102 in Patients with Schizophrenia

March 24, 2026

LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors

March 8, 2026

LB Pharmaceuticals to Participate in Upcoming March Investor Events

March 3, 2026

LB Pharmaceuticals Announces $100.0 Million Private Placement

February 5, 2026

LB Pharmaceuticals Initiates Phase 2 ILLUMINATE-1 Trial in Bipolar Depression, Expanding LB-102 Development Program

January 26, 2026

LB Pharmaceuticals Appoints Minako Pazdera, J.D., Ph.D. as General Counsel

January 21, 2026

LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

January 12, 2026

LB Pharmaceuticals Strengthens Leadership Team with Key Appointments in Corporate Affairs and People & Culture

January 6, 2026

Decks in 2026